Doctors to Discuss Improved Treatments for Gulf Patients With Gastrointestinal Tumors
Specialists Meet on New Findings
Gulf-based doctors will discuss the update in the management and treatment of patients with gastrointestinal stromal tumors (GIST) or neuroendocrine tumors (NET) at upcoming gatherings of medical professionals.
GISTour ’09 (Global Interdisciplinary Specialists Training around the World) on 19 March and NET Tour ’09 on 20 March, interactive road-shows sponsored by Novartis Oncology, will present to the region’s medical community the latest results involving state-of-the-art GIST and NET treatment and management in patients.
Physicians will review data on the latest clinical research on prescription medication involving the use of imatinib to treat GIST and the use of octreotide to treat NET. Reflecting the multidisciplinary aspect of GIST and NET management, invited attendees include medical oncologists, surgical oncologists, gastroenterologists, radiologists and pathologists.
Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas, and, as the most common sarcomas, they can be found most often in the stomach and small intestine. Neuroendocrine tumors (NET) can be found in the digestive system, yet they can arise in other parts of the body such as the lungs and the pancreas.
